Effect of amlodipine on the pharmacokinetics of tacrolimus in rats

Xenobiotica

Volumn 43, Issue 8, 2013, Pages 699-704

  Zhou, Ya Nan ^a   Zhang, Bi Kui ^a   Li, Jing ^a,b   Zuo, Xiao Cong ^a   Yuan, Hong ^a   Yang, Guo Ping ^a   Cheng, Ze Neng ^a   Liu, Zhi ^a   Li, Pei Jiong ^a   Tan, Hong Yi ^a   Zhou, Ling Yun ^a   Wang, Chung Jiang ^a   Yang, Meng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CHILDREN'S HOSPITAL   (China)

Author keywords

Amlodipine; CYP3A2; Drug drug interaction; P glycoprotein; Pharmacokinetics; Tacrolimus

Indexed keywords

AMLODIPINE; CYTOCHROME P450 3A2; TACROLIMUS;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; ENZYME ACTIVITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; AMLODIPINE; ANIMALS; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

RATTUS;

EID: 84879957046     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.756992     Document Type: Article

References (31)

1. Benet LZ, Izumi T, Zhang Y, et al. (1999). Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62:25-31.
2. Bogaards JJ, Bertrand M, Jackson P, et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-52.
3. Choi DH, Choi JS. (2011). Effects of amlodipine on the pharmacokinetics of repaglinide. Kor J Clin Pharm 21:215-23.
4. Desjardins JP, Iversen PL. (1995). Inhibition of the rat cytochrome P450 3A2by an antisense phosphorothioate oligodeoxy-nucleotide in vivo. J Pharmacol Exp Ther 275:1608-13.
5. Drobitch RK, Mclellan RA, Renton KW. (1997). Amlodipine inhibits rat microsomal cytochrome P450-mediated drug biotransformation. J Pharm Sci 86:1501-3.
6. First MR. (2004). Tacrolimus based immunosuppression. J Nephrol 17:S25-31.
7. Hooper Dk, Carle AC, Schuchter J, Goebel J. (2011). Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant 15:88-95.
8. Hutchinson IV. (1997). The mode of action of prograf (FK506)and its significance for long term graft survival. New Horiz Kidney Transplant 1:22-6.
9. Imaoka S, Enomoto K, Oda Y, et al. (1990). Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 255:1385-91.
10. Josefsson M, Zackrisson AL, Ahlner J. (1996). Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 51:189-93.
11. Kagayama A, Tanimoto S, Fujisaki J, et al. (1993). Oral absorption of FK506 in rats. Pharm Res 10:1446-50.
12. Katoh M, Nakajima M, Yamazaki H, Yokoi T. (2000). Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein- mediated transport: comparison with the effects on CYP3A4. Pharm Res 17:1189-97.
13. Kothari J, Nash M, Zaltzman J, Ramesh Prasad GV. (2004). Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther 29:425-30.
14. Kuzuya T, Kobayashi T, Moriyama N, et al. (2003). Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 76:865-8.
15. Leenen FH, Coletta E, Davies RA. (2007). Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. Am J Cardiol 100:531-5.
16. Leroy S, Isapof A, Fargue S, et al. (2010). Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatr Nephrol 25:965-9.
17. Li D, Zhang GL, Lou YQ, et al. (2007). Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 32:89-95.
18. Miki K, Miki N, Hiroshi Y, Tsuyoshi Y. (2001). Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein mediated transport. Eur J Pharm Sci 12:505-13.
19. Saeki T, Ueda K, Tanigawara Yet al. (1993). P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 324:99-102.
20. Sasaki M, Maeda A, Fujimura A. (2001). Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients. Eur J Clin Pharmacol 57:85-6.
21. Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al. (1997). Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother 31:571-5.
22. Shiraga T, Matsuda H, Nagase K, et al. (1994). Membolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver mcirosomes. Biochem Pharmacol 47:727-35.
23. Staatz CE, Tett SE. (2004). Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-53.
24. Tian R, Koyabu N, Takanaga H, et al. (2002). Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 19:802-9.
25. Toupance O, Lavaud S, Canivet E, et al. (1994). Antihypertensive effect of amlodipine and lack of interference with cyclosporine metabolism in renal transplant recipients. Hypertension 24:297-300.
26. Tuteja S, Alloway RR, Johnson JA, Gaber AO. (2001). The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71:1303-7.
27. Venkataramanan R, Swaminathan A, Prasad T, et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-30.
28. Wacher VJ, Wu CY, Benet LZ. (1995). Overlapping substrate specificities and tissues distribution of cytochrome P450 3A and Pglycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-34.
29. Wang EJ, Casciano CN, Clement RP, Johnson WW. (2001). Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 18:432-8.
30. Yukiya H, Hiroaki S, Masahiro S, Inui K. (1998). Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 15:1609-13.
31. Zhang GM, Li L, Chen WQ, et al. (2008). Population pharmacokinetic study of tacrolimus in China renal transplant patients. Yao Xue Xue Bao 43:695-701. Project of Hunan